Sentences with phrase «month trial study»

(6,8) During a six - month trial study on the effects of tai chi there was a 55 % reduction of falls compared to the those in a stretching control group.

Not exact matches

The first trial was supposed to have been completed this month, but the FDA website lists it as pending, which means the study has not been initiated (type in «flibanserin» in the product box here).

In addition, there was no effect on breastfeeding duration when the pacifier was introduced at 1 month of age.280 A more recent systematic review found that the highest level of evidence (ie, from clinical trials) does not support an adverse relationship between pacifier use and breastfeeding duration or exclusivity.281 The association between shortened duration of breastfeeding and pacifier use in observational studies likely reflects a number of complex factors such as breastfeeding difficulties or intent to wean.281 A large multicenter, randomized controlled trial of 1021 mothers who were highly motivated to breastfeed were assigned to 2 groups: mothers advised to offer a pacifier after 15 days and mothers advised not to offer a pacifier.

Although some SIDS experts and policy - makers endorse pacifier use recommendations that are similar to those of the AAP, 272,273 concerns about possible deleterious effects of pacifier use have prevented others from making a recommendation for pacifier use as a risk reduction strategy.274 Although several observational studies275, — , 277 have found a correlation between pacifiers and reduced breastfeeding duration, the results of well - designed randomized clinical trials indicated that pacifiers do not seem to cause shortened breastfeeding duration for term and preterm infants.278, 279 The authors of 1 study reported a small deleterious effect of early pacifier introduction (2 — 5 days after birth) on exclusive breastfeeding at 1 month of age and on overall breastfeeding duration (defined as any breastfeeding), but early pacifier use did not adversely affect exclusive breastfeeding duration.

After six months on the trial, 95 percent of participants reported no problems taking the drug, and while several discontinued treatment for varying periods of time during the study period, the investigators estimate that 90 percent would have tolerated the treatment if they had continued the full two years.

Additional tests — cognitive assessments, measurement of blood markers and MRI brain scans — were conducted at the trial's outset, at 6 months and at the end of the study period.

Last month, Biopure launched a revamped clinical development program, emphasizing testing in Europe, with three phase II clinical trials planned for 2008 to study the impact of its product on heart attack patients, chemotherapy patients with anemia and the terminally ill.

The optical prosthetics, tiny enough to be balanced on a fingertip, dramatically improved the vision of about two thirds of the 206 patients studied in a 24 - month clinical trial, according to a new study published in Archives of Ophthalmology.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

The clear result of this clinical study — that the combination reduced strokes, heart attacks and cardiovascular death by practically 25 per cent compared to either drug alone in both patients with stable coronary or peripheral artery disease — caused the clinical trial to be stopped early, after 23 months, in February 2017.

Of the 10 patients enrolled in the study — a clinical trial designed to evaluate safety and feasibility — none of the participants experienced any dangerous side effects and one patient's disease remained stable after 18 months.

The research team used data from the recently published EORTC 22991 trial to study men with intermediate - risk prostate cancer randomized to either radiation therapy or radiation therapy and 6 months hormone therapy.

The new six - year study, «Cognitive enhancement therapy for adult autism spectrum disorder: Results of an 18 - month randomized clinical trial,» involved 54 adults and was led by Shaun Eack, Ph.D., M.S.W., Pitt's David E. Epperson Professor of Social Work and Psychiatry, and Nancy Minshew, M.D., Pitt professor of psychiatry and neurology.

During a conversation this month in his office at Weill Cornell Medicine in New York City, Fine rattled off more dismal stats, like the many failed clinical trials of experimental drugs for glioblastoma; like the paltry increase in life expectancy for people with glioblastoma from 12 months in 1990 to 15 today; like the stupid (in hindsight) assumptions about how glioblastomas grow and how to study them in mice.

The eight week study, devised as a pragmatic randomized controlled trial, surveyed 80 women experiencing low back pain three to 15 months postpartum.

The article, A pilot study examining functional brain activity 6 months after memory retraining in MS: the MEMREHAB trial, was published online ahead of print on June 14 by Brain Imaging and Behavior.

Although the study began as a randomized trial that divided subjects into four treatment groups (placebo, deprenyl, α - tocopherol, and deprenyl / α - tocopherol), this was terminated early because positive effects of deprenyl were observed and all subjects then received deprenyl for approximately 18 months.

Hillis» preliminary study of six patients continued to show language improvement two weeks and two months later, and a clinical trial funded by the U.S. National Institutes of Health is now underway.

A new study by researchers from the University of Chicago Medicine, based on a 6 - month clinical trial, finds that use of a CGM is cost - effective for adult patients with type 1 diabetes when compared to daily use of test strips.

In two placebo - controlled trials with a total of 380 people who had severe migraines up to 14 days per month, a single dose of a CGRP drug decreased headache days by more than 60 percent (63 percent in one study and 66 percent in the other).

Budimirovic says the current study updated the 2013 recommendations by using a more systematic approach that classified existing outcome measures as either being able to detect shorter - term changes (measures in FXS placebo - controlled trials lasting less than 12 months) or longer - term changes (lasting longer than 12 months) changes and by grading the measures» quantitative properties using the COnsensus - based Standards for the selection of health Measurement Instruments (COSMIN) system, an initiative that aims to improve how health measurement tools are selected.

A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age, according to a clinical trial published in CMAJ (Canadian Medical Association Journal).

To make sure that the patients were really free of the parasite, for instance, they had to be persuaded to travel back to the study clinic and undergo painful lumbar punctures 6, 12, and 18 months after the trial — which isn't easy when patients no longer feel sick.

Our study was small and lasted for six months so further trials need to be carried out to develop these results.

In one case, a patient's tumor completely disappeared and the patient has remained tumor - free for 2.5 years after the trial; going into the study she had an expected survival time of about 6 months, says physician Eilon Kirson of NovoCure.

The organization wants the key outcomes from all studies to be «made available in a clinical trial registry such as ClinicalTrials.gov within 12 months after a study is completed.»

For example, last month's spending bill that established NCATs requests several reports and outside studies of the center's activities and stipulates that it can not support expensive, late - stage clinical trials of the kind typically done by industry.

A new study by researchers at Rice University and institutions in Israel showed patients in a small trial experienced remarkable improvement after two months of treatment.

In this study, to our knowledge the largest randomized clinical trial of robotic - assisted laparoscopic surgery for patients with rectal adenocarcinoma suitable for curative resection, there were no statistically significant differences in the rates of conversion to open laparotomy for robotic - assisted laparoscopic surgery compared with conventional laparoscopic surgery (8.1 % vs 12.2 %, respectively), and there were no statistically significant differences in CRM +, complication rates, or quality of life at 6 months.

According to Col Jerome Kim, Walter Reed Army Institute of Research, US, who was also part of the lead group for the study, apart from the current four doses of vaccines that were given to subjects in the phase III clinical trials in Thailand, they are planning to give a booster does after six months to increase the strength of the vaccine.

While updating my database of human clinical trials using expanded human umbilical cord mesenchymal cells I came across a new article (April, 2016) describing a 36 - month safety in subjects given intravenous cells for in a type 2 diabetes study.

One of the major parameters was the safety of these agents in the respiratory airways and lung parenchyma, since several of these agents are known to cause adverse effects.23 The main adverse effects observed were cough, transient fever and transient decrease in the respiratory functions after the aerosol administration.8, 19, 20 Moreover; it has been observed that excessive deposition of these agents in one site of the respiratory system can induce non-specific side effects in the form of pulmonary edema as observed with many other drugs.16 These side effects were milder when a premedication with bronchodilators and inhaled corticosteroids were administered.8, 19, 20 Until now no long term trial (> 9 months) has been performed since all patients included in previous studies had stage IV non-small cell lung cancer (NSCLC).

Another mouse preclinical screening trial targeted the symptomatic stage (between 9 and 11 months)[44] and a study with a plant extract [99] used 23 - to 24 - month - old mice, but to our knowledge no chemically defined AD drug candidate has been tried at the more pathologically advanced stage used in this study.

This successful strategy has now progressed to the next level, and a study in STEM CELLS provides a comprehensive description of the first - in - man trial in 35 patients and an 18 - month follow - up [3].

Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.

In fact, the study opened just months after the clinical trial collaboration agreement was signed by the Parker Institute, CRI, and BMS in late March.

Reviews of clinical trials on hypnosis have concluded that the evidence of its effectiveness for smoking cessation is insufficient, but other research shows promise: The preliminary results from a small 2007 study of smokers hospitalized with cardiopulmonary diseases showed that the patients who chose to participate in a hypnotherapy session were more likely to be nonsmokers six months later than patients who chose nicotinereplacement therapy (NRT) alone.

The company maintains that the shift simply reflected better understanding of how Alzheimer's affects the brain; cognitive declines happen before functional ones, so detecting the latter would take a longer, more expensive study than an 18 - month trial.

Stress resistance has not been assessed however and so the biological relevance of this finding is currently unknown.32 Several IER trials (75 - 85 % ER on restricted days) in overweight / obese populations have reported reductions in various markers of oxidative stress 37, 41, which in one study was accompanied by a complementary increase in the anti-oxidant uric acid.37 In a direct comparison of IER (75 % ER for two days / week) and CER, both ER strategies displayed equal efficacy in reducing levels of fast - acting advanced oxidation protein products (AOPP) after six months, which displayed a tendency to occur earlier (i.e. at three months) in the IER group.41 Levels of slow - acting (i.e. long term) AOPP tended to decrease in the IER group and increase in the CER group which the authors proposed may have resulted from IER - induced activation of autophagy, a key homeostatic cellular process in which dysfunctional or unnecessary cellular proteins are degraded and recycled.41 On the other hand, a follow - up study using similar IER / CER protocols demonstrated comparable reductions in AOPP in both groups after three months.48 Summary and Future Research Directions

To date, the longest weight - loss trial of IER, lasting six months, demonstrated comparable weight loss amongst overweight / obese women assigned to IER (two ~ 75 % ER days per week) and CER (25 % ER / day) groups at all tested time points.41 Whilst this suggests that IER is no easier to follow in the long - term, the limited variety of foods permitted on restricted days in this particular study (milk, fruits and vegetables) may have limited the acceptability and long - term sustainability of this protocol.

A systematic review of all the dietary trials showed that much of the benefits of a low carbohydrate approach faded by 1 year.In the follow up to the DIRECT study, it was found that by 12 months, weight had started to regain in all patients, including the low carbohydrate group.

A dosage of 200 mcg per day has been found to reduce thyroid antibodies in clinical trials, in some studies selenium cut the antibodies in half within three months....

A study published in the journal of Complimentary Therapies in Clinical Practice revealed that eating cumin regularly decreased body fat percentage by 14.64 % compared to 4.91 % in those who did not eat cumin in the three month trial.

The investigators of this study, which was done at Arizona State University, was intrigued by a government, randomized clinical trial which showed that dieters following the Atkins diet showed greater weight loss at 3 to 6 months.

The scientists then performed a second study with similar objectives; 48 adults with poorly controlled type 2 diabetes were all supplemented with berberine in a three month trial.

A 2013 study found that 1000mg / day improved cognitive function at 6 and 12 months post-stroke (specifically in areas of attention, executive function and temporal orientation), while another trial showed that initiating citicoline within 24 hours after the occurrence of a stroke «increases the probability of complete recovery at three months.»

In a recent trial for ulcerative colitis, a multicenter, randomized, placebo - controlled, double - blind study found that more than 50 percent of patients achieved remission within just one month on curcumin compared to none of the patients who received the placebo.

In a famous 13 - month - long randomized controlled trial of plant - based diets for rheumatoid arthritis, patients were put on a vegan diet for three and a half months, and then switched to an egg - free lactovegetarian diet for the remainder of the study.

A clinical trial in Spain was published this month (December 2015) studying the effects of coconut oil on Alzheimer's, and the results were very promising.

The therapeutic dotential of dietary precursor modulation by a fish - oil - supplemented diet (n - 3 fatty acids), such as eicosapentaenoic acid (C20: 5,n - 3) and docosahexaenoic acid (C22: 6,n - 3) in the therapy of ulcerative colitis has been shown to result in a 35 % to 50 % decrease in neutrophil production of LTB4.28 Significant improvement in symptoms and histologic appearance of the rectal mucosa has been observed in several small series of patients with Crohn's disease and ulcerative colitis given fish oil at 3 to 4 g daily for 2 to 6 months in uncontrolled studies.29 However, a larger, randomized, double - blind trial comprising 96 patients with ulcerative colitis failed to reveal any benefit in remission maintenance or treatment of relapse on 4.5 g of eicosapentaenoic acid daily, despite a significant reduction in LTB4 synthesis by blood peripheral polymorphonuclear cells.30 It should be emphasized, however, that the anti-inflammatory actions of the fish oils, in addition to inhibition of LTB4, include suppression of IL - 1 and platelet activating factor synthesis and scavenging of free oxygen radicals.30 The impact of increased lipid peroxidation after fish oil supplementation should be considered when altering the n - 6: n - 3 fatty acid ratio.31 Antioxidant supplementation may be able to counteract the potentially adverse effects of n - 3 fatty acids.